Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CLARIX™ 100 & CLARIX CORD 1K for Discectomy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03113786
Recruitment Status : Completed
First Posted : April 14, 2017
Last Update Posted : July 15, 2020
Sponsor:
Information provided by (Responsible Party):
Amniox Medical, Inc.

Brief Summary:
The purpose of the study is to evaluate the efficacy of CLARIX™ 100 and CLARIX™ CORD 1K as a tissue barrier when used as an annular patch in discectomy patients with low back & leg pain when compared to traditional discectomy patient outcomes. This will be a 120 patient, prospective randomized study model over a 5 year post-operative period.

Condition or disease Intervention/treatment Phase
Protruded Disk Other: CLARIX™100 Other: CLARIX CORD 1K Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Efficacy of Amniotic Tissue (CLARIX 100 & CLARIX CORD 1K) in Pain Reduction and Improvement of Function in Low Back & Leg Pain in Discectomy Patients
Actual Study Start Date : November 2, 2011
Actual Primary Completion Date : April 21, 2020
Actual Study Completion Date : April 21, 2020

Arm Intervention/treatment
No Intervention: Standard of Care
Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
Active Comparator: CLARIX™100
Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
Other: CLARIX™100
CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).

Active Comparator: CLARIX CORD 1K
Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
Other: CLARIX CORD 1K
CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues & Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.




Primary Outcome Measures :
  1. Difference in low back & leg pain [ Time Frame: 5 years ]
    To determine at various time points up to 5 years what, if any, difference there is between the three groups of 40 patients by using the Oswestry Disability Index scales for both back & leg pain

  2. Difference in low back & leg pain [ Time Frame: 5 years ]
    To determine at various time points up to 5 years what, if any, difference there is between the three groups of 40 patients by using the SF-12 scale for both back & leg pain

  3. Difference in low back & leg pain [ Time Frame: 5 years ]
    To determine at various time points up to 5 years what, if any, difference there is between the three groups of 40 patients by using the VAS for both back & leg pain



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients between 18 and 90 years of age
  • Patient is able to understand the aims and objectives of the trial and the trial procedures
  • Patient is willing to give written informed consent to the trial
  • Patient is able to follow up with regularly scheduled visits with and phone calls from Dr. Anderson and his research staff
  • Diagnosed with lumbar protruding disc
  • Suffer from radiating leg pain and low back pain that has failed a minimum of 6 months of conservative (non-operative) treatment options

Exclusion Criteria:

  • Participation in clinical trial involving therapy for back pain within 30 days of screening
  • Prior back surgery at the same level
  • Inability to walk independently (adaptive devices such as walkers or canes are allowed)
  • Relation (whether direct or indirect) to, student of, employee of, colleague of, indebted to the primary investigator, host institution or sponsoring company
  • Receipt of corticosteroids, immunosuppressive agents, radiation therapy or chemotherapy within 1 month prior to visit
  • Pregnancy or planning to become pregnant during study period
  • Body Mass Index >50
  • Patients with chronic diseases such as Crohn's disease, severe renal failure (serum creatinine 2.5 mg/dL or subject on hemodialysis), severe hepatic insufficiency: known cirrhosis, any degree of ascites, serum transaminases more than 3 times the upper limit of normal, life expectancy of less than one year, uncompensated or uncontrolled right sided heart failure with associated edema
  • Severe anemia, hemoglobin <8.5 mg/dL
  • Active, local or systemic malignancy such as lung cancer or leukemia
  • Severe hypertension (systolic blood pressure greater than or equal to 200 mmHg or diastolic blood pressure greater than or equal to 100 mmHg)
  • Severe hypoxia, with chronic oxygen or ventilation therapy
  • History of collagen vascular disease or sickle cell anemia
  • Active rheumatoid arthritis
  • Systemic antibiotic therapy for any indication within 10 days of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03113786


Locations
Layout table for location information
United States, Pennsylvania
Rothman Institute
Bensalem, Pennsylvania, United States, 19020
Sponsors and Collaborators
Amniox Medical, Inc.
Investigators
Layout table for investigator information
Study Chair: Scheffer Tseng, MD, PhD Tissue Tech Inc.
Layout table for additonal information
Responsible Party: Amniox Medical, Inc.
ClinicalTrials.gov Identifier: NCT03113786    
Other Study ID Numbers: CR-1001
First Posted: April 14, 2017    Key Record Dates
Last Update Posted: July 15, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Amniox Medical, Inc.:
Discectomy
Lumbar discectomy
Protruding disc